176 related articles for article (PubMed ID: 31049424)
1. Functional and pharmacological characterization of an S5 domain hERG mutation associated with short QT syndrome.
Butler A; Zhang Y; Stuart AG; Dempsey CE; Hancox JC
Heliyon; 2019 Apr; 5(4):e01429. PubMed ID: 31049424
[TBL] [Abstract][Full Text] [Related]
2. Action potential clamp characterization of the S631A hERG mutation associated with short QT syndrome.
Butler A; Zhang Y; Stuart AG; Dempsey CE; Hancox JC
Physiol Rep; 2018 Sep; 6(17):e13845. PubMed ID: 30175559
[TBL] [Abstract][Full Text] [Related]
3. Identification through action potential clamp of proarrhythmic consequences of the short QT syndrome T618I hERG 'hotspot' mutation.
Du C; Zhang H; Harmer SC; Hancox JC
Biochem Biophys Res Commun; 2022 Mar; 596():49-55. PubMed ID: 35114584
[TBL] [Abstract][Full Text] [Related]
4. Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.
El Harchi A; Melgari D; Zhang YH; Zhang H; Hancox JC
PLoS One; 2012; 7(12):e52451. PubMed ID: 23300672
[TBL] [Abstract][Full Text] [Related]
5. Electrophysiological characterization of the modified hERG
Zhang Y; Dempsey CE; Hancox JC
Physiol Rep; 2020 Oct; 8(20):e14568. PubMed ID: 33091232
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of the short QT N588K mutation at 37 degrees C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study.
McPate MJ; Zhang H; Adeniran I; Cordeiro JM; Witchel HJ; Hancox JC
J Physiol Pharmacol; 2009 Mar; 60(1):23-41. PubMed ID: 19439805
[TBL] [Abstract][Full Text] [Related]
7. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
Ridley JM; Milnes JT; Hancox JC; Witchel HJ
J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
[TBL] [Abstract][Full Text] [Related]
8. Suppression of the hERG potassium channel response to premature stimulation by reduction in extracellular potassium concentration.
Melgari D; Du C; El Harchi A; Zhang Y; Hancox JC
Physiol Rep; 2014 Oct; 2(10):. PubMed ID: 25318749
[TBL] [Abstract][Full Text] [Related]
9. Serine mutation of a conserved threonine in the hERG K
Al-Moubarak E; Zhang Y; Dempsey CE; Zhang H; Harmer SC; Hancox JC
Biochem Biophys Res Commun; 2020 Jun; 526(4):1085-1091. PubMed ID: 32321643
[TBL] [Abstract][Full Text] [Related]
10. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
Du C; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2014 Sep; 74(100):220-30. PubMed ID: 24877995
[TBL] [Abstract][Full Text] [Related]
11. The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees C.
McPate MJ; Duncan RS; Milnes JT; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2005 Aug; 334(2):441-9. PubMed ID: 16011830
[TBL] [Abstract][Full Text] [Related]
12. The hERG K(+) channel S4 domain L532P mutation: characterization at 37°C.
Zhang YH; Colenso CK; Sessions RB; Dempsey CE; Hancox JC
Biochim Biophys Acta; 2011 Oct; 1808(10):2477-87. PubMed ID: 21777565
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the hERG potassium channel by phenanthrene: a polycyclic aromatic hydrocarbon pollutant.
Al-Moubarak E; Shiels HA; Zhang Y; Du C; Hanington O; Harmer SC; Dempsey CE; Hancox JC
Cell Mol Life Sci; 2021 Dec; 78(23):7899-7914. PubMed ID: 34727194
[TBL] [Abstract][Full Text] [Related]
14. Impact of the whole-cell patch-clamp configuration on the pharmacological assessment of the hERG channel: trazodone as a case example.
Rodriguez-Menchaca AA; Ferrer T; Navarro-Polanco RA; Sanchez-Chapula JA; Moreno-Galindo EG
J Pharmacol Toxicol Methods; 2014; 69(3):237-44. PubMed ID: 24412489
[TBL] [Abstract][Full Text] [Related]
15. Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.
Zhang Y; Colenso CK; El Harchi A; Cheng H; Witchel HJ; Dempsey CE; Hancox JC
Biochem Pharmacol; 2016 Aug; 113():24-35. PubMed ID: 27256139
[TBL] [Abstract][Full Text] [Related]
16. A novel mutation in the KCNH2 gene associated with short QT syndrome.
Sun Y; Quan XQ; Fromme S; Cox RH; Zhang P; Zhang L; Guo D; Guo J; Patel C; Kowey PR; Yan GX
J Mol Cell Cardiol; 2011 Mar; 50(3):433-41. PubMed ID: 21130771
[TBL] [Abstract][Full Text] [Related]
17. The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
Hisajima N; Hata Y; Kinoshita K; Fukushima T; Nishida N; Kano M; Tabata T
Biol Pharm Bull; 2015; 38(5):781-4. PubMed ID: 25947924
[TBL] [Abstract][Full Text] [Related]
18. The variant hERG/R148W associated with LQTS is a mutation that reduces current density on co-expression with the WT.
Mechakra A; Vincent Y; Chevalier P; Millat G; Ficker E; Jastrzebski M; Poulin H; Pouliot V; Chahine M; Christé G
Gene; 2014 Feb; 536(2):348-56. PubMed ID: 24334129
[TBL] [Abstract][Full Text] [Related]
19. Modulation of I(Kr) inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome.
Cordeiro JM; Brugada R; Wu YS; Hong K; Dumaine R
Cardiovasc Res; 2005 Aug; 67(3):498-509. PubMed ID: 16039272
[TBL] [Abstract][Full Text] [Related]
20. A Heterozygous Missense hERG Mutation Associated with Early Repolarization Syndrome.
Cheng YJ; Yao H; Ji CC; Chen XM; Fan J; Liu LJ; Wu SH
Cell Physiol Biochem; 2018; 51(3):1301-1312. PubMed ID: 30481776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
